Evidence map›Paper›PMID 37927689›Full record

ReviewCureus2023

Charting the Progress of Epilepsy Classification: Navigating a Shifting Landscape.

Alaa Abdelsamad, Meet Popatbhai Kachhadia, Talha Hassan, Lakshya Kumar, Faisal Khan, Indrani Kar, Uttam Panta, Wirda Zafar, Fnu Sapna, Giustino Varrassi and 2 more

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 6 countries.

Alaa AbdelsamadResearch and Development, Michigan State University, East Lansing, USA.
Meet Popatbhai KachhadiaInternal Medicine, PDU (Pandit Dindayal Upadhyay) College, Civil Hospital Campus, Rajkot, IND.
Talha HassanInternal Medicine, KEMU (King Edward Medical University) Mayo Hospital, Lahore, PAK.
Lakshya KumarGeneral Medicine, PDU (Pandit Dindayal Upadhyay) Medical College, Rajkot, IND.
Faisal KhanMedicine, Dow University of Health Sciences (DUHS), Karachi, PAK.
Indrani KarMedicine, Lady Hardinge Medical College, New Delhi, IND.
Uttam PantaMedicine, Chitwan Medical College, Bharatpur, NPL.
Wirda ZafarMedicine, University of Medicine and Health Sciences, Toronto, CAN.
Fnu SapnaPathology, Albert Einstein College of Medicine, New York, USA.
Giustino VarrassiPain Medicine, Paolo Procacci Foundation, Rome, ITA.
Mahima KhatriMedicine and Surgery, Dow University of Health Sciences (DUHS), Karachi, PAK.
Satesh KumarMedicine and Surgery, Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, PAK.
Dow University of Health Sciences · PKAlbert Einstein College of Medicine · USChitwan Medical College · NPDeen Dayal Upadhyay Hospital · INFondazione Roma · ITGovernment Medical College · INKing Edward Medical University · PKLady Hardinge Medical College · INMichigan State University · USShaheed Mohtarma Benazir Bhutto Medical University · PKUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy, a neurological disorder characterized by recurrent seizures, has witnessed a remarkable transformation in its classification paradigm, driven by advances in clinical understanding, neuroimaging, and molecular genetics. This narrative review navigates the dynamic landscape of epilepsy classification, offering insights into recent developments, challenges, and the promising horizon. Historically, epilepsy classification relied heavily on clinical observations, categorizing seizures based on their phenomenology and presumed etiology. However, the field has profoundly shifted from a symptom-based approach to a more refined, multidimensional system. One pivotal aspect of this evolution is the integration of neuroimaging techniques, particularly magnetic resonance imaging (MRI) and functional imaging modalities. These tools have unveiled the intricate neural networks implicated in epilepsy, facilitating the identification of distinct brain abnormalities and the categorization of epilepsy subtypes based on structural and functional findings. Furthermore, the role of genetics has become increasingly prominent in epilepsy classification. Genetic discoveries have not only unraveled the molecular underpinnings of various epileptic syndromes but have also provided valuable diagnostic and prognostic insights. This narrative review delves into the expanding realm of genetic testing and its impact on tailoring treatment strategies to individual patients. As the classification landscape evolves, there are accompanying challenges. The narrative review underscores the transformative potential of artificial intelligence and machine learning in epilepsy classification. These technologies hold promise in automating the analysis of complex neuroimaging and genetic data, offering enhanced accuracy and efficiency in epilepsy diagnosis and classification. In conclusion, navigating the shifting landscape of epilepsy classification is a journey marked by progress, complexity, and the prospect of improved patient care. We are charting a course toward more precise diagnoses and tailored treatments by embracing advanced neuroimaging, genetics, and innovative technologies. As the field continues to evolve, collaborative efforts and a holistic understanding of epilepsy's diverse manifestations will be instrumental in harnessing the full potential of this dynamic landscape.

Indexed as

artificial intelligence in epilepsyepilepsy classificationgenetic insightsneuroimaging advancesprecision medicineseizure phenomenology

Identifiers

PMID37927689
PMCPMC10624359
OpenAlexW4387342896

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.